REV 5901

• Description :

  REV 5901 is a competitive and orally active antagonist of leukotriene receptor, with a Ki of 0.7 μM. REV 5901 is also a 5-lipoxygenase inhibitor. REV 5901 can be used for the research of asthma in which leukotriene release be involved. REV 5901 can be used for the study of colon carcinoma[1][2][3].

• CAS Number :

  [101910-24-1]

• UNSPSC :

  12352005

• Hazard Statement :

  H315, H319, H335

• Target :

  Leukotriene Receptor; Lipoxygenase

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein; Metabolic Enzyme/Protease

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Cancer; Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/rev-5901.html

• Purity :

  99.9

• Solubility :

  DMF : 36 mg/mL (ultrasonic; warming)

• Smiles :

  OC(CCCCC)C1=CC=CC(OCC2=NC3=CC=CC=C3C=C2)=C1

• Molecular Formula :

  C22H25NO2

• Molecular Weight :

  335.44

• Precautions :

  H315, H319, H335

• References & Citations :

  [1]Inwegen RGV, et, al. REV 5901: an orally effective peptidoleukotriene antagonist, detailed biochemical/pharmacological profile. J Pharmacol Exp Ther. 1987 Apr;241 (1) :117-24.|[2]Anderson G, et, al. Effects of REV 5901, a 5-lipoxygenase inhibitor and leukotriene antagonist, on pulmonary responses to platelet activating factor in the guinea-pig. Br J Pharmacol. 1988 Aug;94 (4) :1115-22. |[3]Paskaš S, et al. Carborane-Based Analog of Rev-5901 Attenuates Growth of Colon Carcinoma In Vivo. Molecules. 2022 Jul 14;27 (14) :4503.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C, 3 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported